Literature DB >> 8098014

Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.

W D Foulkes1, D M Black, G W Stamp, E Solomon, J Trowsdale.   

Abstract

Frequent loss of heterozygosity (LOH) on both arms of chromosome 17 has been described in ovarian carcinoma (OC) by a number of groups, and the recent fine mapping of an inherited breast-ovarian cancer gene (brcAI) to a small region at 17q12-21 has focused interest on this area. We studied 28 sporadic OCs with 21 markers at 18 loci on chromosome 17 (5 on 17p and 13 on 17q). LOH on 17p was 78%, and always involved p53. In 86% of cases showing LOH, all informative markers on chromosome 17 showed reduction to homozygosity. Using 6 markers flanking the brcAI locus on 17q, LOH was 75%, but only one tumour showed LOH with telomeric retention. The data therefore suggest that small deletions on chromosome 17 are very uncommon in sporadic OC. No genomic rearrangements by Southern blotting were seen in the brcAI candidate gene estradiol 17 beta dehydrogenase 2 (17hsd2), or in erbB2, prohibition (phb) and nmeI (previously nm23-HI). LOH on chromosome 17 was more common in high-grade, late-stage carcinomas, and no LOH was seen in any benign or borderline tumour. This study has clearly demonstrated that LOH at any one site on chromosome 17 is most commonly explained by LOH over the whole of the chromosome. We consider possible reasons for the absence of small deletions on chromosome 17 in OC.

Entities:  

Mesh:

Year:  1993        PMID: 8098014     DOI: 10.1002/ijc.2910540210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings.

Authors:  M Saegusa; I Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Molecular genetics of familial breast-ovarian cancer.

Authors:  E J van Rensburg; B A Ponder
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

3.  Tumour suppressor genes in ovarian cancer.

Authors:  W Foulkes
Journal:  BMJ       Date:  1993-10-16

4.  Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.

Authors:  Karen M Chisholm; Barbara A Goff; Rochelle Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Cancer Genet Cytogenet       Date:  2008-05

5.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

Authors:  A K Godwin; L Vanderveer; D C Schultz; H T Lynch; D A Altomare; K H Buetow; M Daly; L A Getts; A Masny; N Rosenblum
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

6.  The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Authors:  Paulina M Wojnarowicz; Kathleen Klein Oros; Michael C J Quinn; Suzanna L Arcand; Karen Gambaro; Jason Madore; Ashley H Birch; Manon de Ladurantaye; Kurosh Rahimi; Diane M Provencher; Anne-Marie Mes-Masson; Celia M T Greenwood; Patricia N Tonin
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

Review 7.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

8.  Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.

Authors:  J Papp; B Csokay; P Bosze; Z Zalay; J Toth; B Ponder; E Olah
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Authors:  P Wojnarowicz; K Gambaro; M de Ladurantaye; M C J Quinn; D Provencher; A-M Mes-Masson; P N Tonin
Journal:  Oncogenesis       Date:  2012-09-10       Impact factor: 7.485

10.  MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.

Authors:  W D Foulkes; G W Stamp; S Afzal; N Lalani; C P McFarlane; J Trowsdale; I G Campbell
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.